A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits

Vaccine

Volumn 28, Issue 28, 2010, Pages 4445-4451

  Gao, LuLu ^a   Yu, Shouyi ^a   Chen, Qing ^a   Duan, Zhaojun ^b   Zhou, Jie ^a   Mao, Chen ^a   Yu, Dexian ^a   Zhu, Wenchang ^a   Nie, Jun ^a   Hou, Yunde ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Nasal spray; Randomized controlled trial; Recombinant human interferon 2b; Viral respiratory infection

Indexed keywords

NOSE SPRAY; RECOMBINANT ALPHA2B INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOGLOBULIN M; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ADENOVIRUS; ADENOVIRUS INFECTION; ADULT; ARMY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PARAINFLUENZA VIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; BLOOD; CHINA; DOUBLE BLIND PROCEDURE; INTRANASAL DRUG ADMINISTRATION; RESPIRATORY TRACT INFECTIONS; SOLDIER; VIROLOGY; VIRUS DISEASES; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHINA; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN M; INTERFERON ALFA-2B; MALE; MILITARY PERSONNEL; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES; YOUNG ADULT; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 77953025376     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.062     Document Type: Article

References (29)

1. Gaydos J.C., Top Jr. F.H., Hodder R.A., and Russell P.K. Swine influenza A outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis 12 1 (2006) 23-28
2. McNeill K.M., Vaughn B.L., Brundage M.B., Li Y., Poropatich R.K., and Gaydos J.C. Clinical presentations for influenza and influenza-like illness in young, immunized soldiers. Mil Med 170 1 (2005) 94-97
3. Sencer D.J., and Millar J.D. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 12 1 (2006) 29-33
4. Ison M.G., Mills J., Openshaw P., Zambon M., Osterhaus A., and Hayden F. Current research on respiratory viral infections: fourth international symposium. Antiviral Res 55 2 (2002) 227-228
5. Kolavic-Gray S.A., Binn L.N., Sanchez J.L., Cersovsky S.B., Polyak C.S., Mitchell-Raymundo F., et al. Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. Clin Infect Dis 35 7 (2002) 808-818
6. Löwy I. The social history of medicine: beyond the local. Soc Hist Med 20 3 (2007) 465-481
7. Lyons A., Longfield J., Kuschnera R., Straight T., Binn L., Seriwatana J., et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 26 23 (2008) 2890-2898
8. Peiruo Duan, Chungang Ma, Lili Zhang, Hongyan Han, Ronghui Zhang, Zhao Hua, et al. Influenza surveillance on the army population. J Prev Med Chin PLA 20 1 (2002) 23-26
9. Katerina M.A., Emmanouil A., and Demosthenes B. Interferon and their application in the diseases of the lung. Chest 123 1 (2003) 209-216
10. Higgins P.G., Barrow G.I., Tyrrell D.A., Isaacs D., and Gauci C.L. The efficacy of intranasal interferon alpha-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 14 1 (1990) 3-10
11. Turner R.B., Felton A., Kosak K., Kelsey D.K., and Meschievitz C.K. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 154 3 (1986) 443-447
12. Sung R.Y., Yin J., Oppenheimer S.J., Tam J.S., and Lau J. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch Dis Child 69 4 (1993) 440-442
13. Douglas R.M., Moore B., Miles H.B., and Pinnock C.B. Could preventive intranasal interferon lower the morbidity in children prone to respiratory illness?. Med J Aust 152 10 (1990) 527-528 524
14. Monto A.S., Shope T.C., Schwartz S.A., and Albrecht J.K. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis 154 1 (1986) 128-133
15. Scott G.M., Onwubalili J.K., Robinson J.A., Doré C., Secher D.S., and Cantell K. Tolerance of one-month intranasal interferon. J Med Virol 17 2 (1985) 99-106
16. Samo T.C., Greenberg S.B., Palmer J.M., Couch R.B., Harmon M.W., and Johnson P.E. Intranasal applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J Infect Dis 150 2 (1984) 181-188
17. Hayden F.G., Mills S.E., and Johns M.E. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J Infect Dis 148 5 (1983) 914-921
18. Forrest G.L. Glossary of evidence-based terms. J Evid Base Dent Pract 8 (2008) 55-61
19. Abed Y., and Boivin G. Treatment of respiratory virus infections. Antiviral Res 70 2 (2006) 1-16
20. Kitchen L.W., and Vaughn D.W. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 26 41 (2007) 7017-7030
21. Russell K.L., Ryan M.A.K., Hawksworth A., Freed E., Irvine M., Daum L.T., et al. Effectiveness of the 2003-2004 influenza vaccine among U. S. military basic trainees: a year of suboptimal match between vaccine and circulating strain. Vaccine 23 16 (2005) 1981-1985
22. Amelio R., Biselli R., Calì G., and Peragallo M.S. Vaccination policies in the military: an insight on influenza. Vaccine 20 Suppl. 5 (2002) B36-B39
23. Ströher U., DiCaro A., and Li Y. Severe acute respiratory syndrome-related severe coronavirus is inhibited by interferon-alpha. J Infect Dis 189 7 (2004) 1164-1167
24. Duan Z.J., Zhang L.L., Xie Z.P., Yu Z., Zhang L.P., Zhang B., et al. Anti-SARS virus activities of different recombinant human interferons in cell culture system. Chinese J Exp Clin Virol 17 13 (2003) 205-208
25. Gao H., Zhang L.L., Wwi Q., Duan Z.J., Tu X.M., Yu Z., et al. Preventive and therapeutic effects of recombinant IFN-b nasal spray on SARS-CoV infection in Macaca mulata. Chinese J Exp Clin Virol 19 3 (2005) 207-210
26. Graat J.M., Schouten E.G., Heijnen M.L., Kok F.J., Pallast E.G.M., de Greeff S.C., et al. A prospective, community-based study on virologic assessment among elderly people with and without Symptoms of acute respiratory infection. J Clin Epiemiol 56 12 (2003) 1218-1223
27. Alper C.M., Doyle W.J., Winther B., and Hendley J.O. Upper respiratory virus detection without parent-reported illness in children is virus-specific. J Clin Virol 43 1 (2008) 120-122
28. Chen Q., Zhang L.L., Yu D.X., Yu Z., Liu Y., Zhang L.P., et al. A field trial for evaluating the safety of recombinant human interferon α-2b for nasal spray. Chinese J Exp Clin Virol 19 3 (2005) 211-215
29. Jefferson T.O., and Tyrrell D. Vaccines for the common cold (protocol for a Cochrane review). The Cochrane Library, Issue 3 (2004), John Wiley & Sons, Ltd., Chichester, UK